Severe hemophilia A (<1% FVIII:C) research hub

(21824) A phase 3, single group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A

This study is testing a new medicine called Jivi for boys aged 7-11 with severe haemophilia A. It's looking at how safe Jivi is, whether it causes strong reactions, or if the body develops resistance to it, specifically during the first four doses.